Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata

被引：0
|
作者：
Dai, Z. [1 ]
Loesch, E. [1 ]
Chen, J. C. [1 ]
Wang, E. [1 ]
Lee, E. [1 ]
Christiano, A. [1 ]
机构：
[1] Columbia Univ, Dermatol, New York, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
695
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [41] CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models
    Li, Dan
    Shan, Song
    Mao, Xuhua
    Zhao, Yiru
    Chen, Beizhong
    Xiong, Qiuyun
    Pan, Desi
    Huang, Shengjian
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2024, 46 (04) : 529 - 537
  • [42] Targeting JAK3 for immune suppression and allograft acceptance
    Kirken, RA
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3268 - 3270
  • [43] INTERACTION OF IL-2R-BETA AND GAMMA(C) CHAINS WITH JAK1 AND JAK3 - IMPLICATIONS FOR XSCID AND XCID
    RUSSELL, SM
    JOHNSTON, JA
    NOGUCHI, M
    KAWAMURA, M
    BACON, CM
    FRIEDMANN, M
    BERG, M
    MCVICAR, DW
    WITTHUHN, BA
    SILVENNOINEN, O
    GOLDMAN, AS
    SCHMALSTIEG, FC
    IHLE, JN
    OSHEA, JJ
    LEONARD, WJ
    SCIENCE, 1994, 266 (5187) : 1042 - 1045
  • [44] Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
    Haan, Claude
    Rolvering, Catherine
    Raulf, Friedrich
    Kapp, Manuela
    Drueckes, Peter
    Thoma, Gebhard
    Behrmann, Iris
    Zerwes, Hans-Guenter
    CHEMISTRY & BIOLOGY, 2011, 18 (03): : 314 - 323
  • [45] Tofacitinib downregulates JAK1 and JAK3 on human intestinal monocytes and macrophages without affecting dendritic cells phenotype or function
    Arribas-Rodriguez, Elisa
    De Prad, Angel
    de Andres, Beatriz
    Velayos, Benito
    Barrio, Jesus
    Romero, Alejandro
    Garcia-Alonso, Francisco Javier
    Martin-Munoz, Alvaro
    Garrote, Jose A.
    Arranz, Eduardo
    Fernandez-Salazar, Luis
    Bernardo, David
    JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2025, 10
  • [46] Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
    Guttman-Yassky, E.
    Pavel, A. B.
    Page, K.
    Diaz, A.
    Banerjee, A.
    King, B.
    Zhang, W.
    Zhu, L.
    Banfield, C.
    Cox, L. A.
    Vincent, M.
    Dowty, M.
    Peeva, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S94 - S94
  • [47] Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3
    Malerich, Jeremiah P.
    Lam, Jennifer S.
    Hart, Barry
    Fine, Richard M.
    Klebansky, Boris
    Tanga, Mary J.
    D'Andrea, Annalisa
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7454 - 7457
  • [48] Complete genomic organization and promoter analysis of the round-spotted pufferfish JAK1, JAK2, JAK3, and TYK2 genes
    Leu, JH
    Yan, SJ
    Lee, TF
    Chou, CM
    Chen, ST
    Hwang, PP
    Chou, CK
    Huang, CJ
    DNA AND CELL BIOLOGY, 2000, 19 (07) : 431 - 446
  • [49] Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
    Gilhar, A.
    Keren, A.
    Ahmad, W.
    Walker, P.
    Howell, M.
    Hasan, F.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S358 - S358
  • [50] Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib-Revisiting the immunomechanisms of the JAK pathway
    Sardana, Kabir
    Bathula, Savitha
    Khurana, Ananta
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2023, 14 (04) : 465 - 474
12345